Articles tagged with Cell Therapies
A new CAR NK cell engineering approach requires two signals to eliminate target cells, improving tumor specificity and enhancing anti-tumor activity. This strategy mitigates NK cell exhaustion and fratricide, leading to better focus on and attack of only the tumor cells.
Researchers have developed a new approach to test the efficacy of multiple anticancer drug combinations simultaneously, rapidly, and accurately. Combi-seq overcomes limitations of conventional technologies by using microfluidics to carry out large-scale experiments with small sample volumes.
The NCCN Annual Congress on Hematologic Malignancies will address key findings on chronic lymphocytic leukemia management and CAR T-cells in diffuse large B-cell lymphoma. The event also features updates on immunotherapies in multiple myeloma treatment.
Monon Bioventures has received a grant to develop a novel glioblastoma treatment using armed natural killer cells. The treatment, created by Purdue University researcher Sandro Matosevic, shows promise in preclinical proof of concept and aims to manufacture the therapeutic for clinical studies.
A team from UNIGE and HUG identified a protein regulation mechanism that reduces melanoma cells' capacity to adapt and resist treatment. They found that targeting this mechanism with an enzyme inhibitor reduces therapeutic resistance in all melanoma cells.
Researchers discovered a type of triple-negative breast cancer cell that can trigger dormancy, evading therapies and allowing for efficient survival in distant organs. This finding highlights the need for more selective therapeutic strategies targeting both dividing and invasive dormant cells.
A team of researchers has identified TSG101 as a crucial regulator of the PARP1 enzyme, which is responsible for repairing DNA damage. In cancer cells with BRCA mutations, TSG101 is essential for PARP1 activation, making it a promising target for cancer treatment.
Researchers have made a breakthrough in treating autoimmune diseases by using genetically modified CAR T cells to target and destroy harmful B cells. This innovative therapy has shown promising results in six young patients with severe forms of systemic lupus erythematosus, curing them completely without returning.
Researchers create mammalian cells that synthesize a noncanonical amino acid, which can be used to make therapeutic proteins. The discovery could lead to the development of new treatments for various diseases.
A study by Kyoto University Professor Misao Fujita found that Japan's Act on the Safety of Regenerative Medicine lacks key provisions to prevent unproven treatments from being administered to patients. The lack of scientific verification and clear definitions for medical innovations and interventions are major concerns.
Bladder cancer researchers discovered a subset of CD8 T cells that adapts to tumor evasion strategies, offering a strategy to reduce tumor cells' ability to fight them off. The study also identified potential ways to make immunotherapy more effective against this deadly cancer by targeting the HLA-E/NKG2A axis.
Researchers at Tokyo Metropolitan University discovered that a protein excreted by type I muscle fibers can differentiate surrounding myoblasts into type I fibers, upending the notion that fiber ratios are fixed at birth. This finding has significant implications for treating conditions such as type 2 diabetes and aging populations.
A phase 3 study shows that tumour-infiltrating lymphocytes (TIL) therapy significantly improves progression-free survival compared to standard immunotherapy in patients with advanced melanoma. The treatment reduces disease progression or death by 50% in patients treated with TILs.
A study led by researchers at the University of Arizona Health Sciences has uncovered a possible path for improving T cell therapies. The study found that the CD4 molecule plays a more active role in regulating T cell receptor signaling, allowing for even more powerful versions of T cell therapy.
A new study from Washington University School of Medicine suggests that levels of neurofilament light chain (NfL) in the blood can predict neurotoxic side effects in patients undergoing CAR-T cell therapy. High NfL levels are present even before treatment begins and remain elevated throughout treatment.
Scientists have discovered three proteins with therapeutic potential to prevent cardiac damage and preserve cardiac function after a heart attack. The proteins, Chrdl1, Fam3c, and Fam3b, were identified through an innovative technology called FunSel that screens human proteins for protective effects.
Researchers found that patients with longer progression-free survival after BCMA-targeted CAR T-cell therapy had more diverse baseline T-cell repertoires, fewer markers of immune exhaustion, and distinct changes to immune cell populations. These factors were associated with improved responses to the treatment.
A new study identifies how the suppression of a specific transcription gene triggers changes that impair oligodendrocyte function in Huntington's disease. The researchers believe replacing or fixing defective glia cells may prove a far easier proposition than replenishing neurons lost in the disease.
Researchers developed a light-based therapy, photodynamic therapy (aPDT), to combat antibiotic-resistant bacteria. The treatment showed promise in weakening bacteria, allowing lower doses of current antibiotics to effectively eliminate them.
A combination of immunotherapy and virotherapy using myxoma virus provides new hope for patients with treatment resistant cancers. The approach boosts the immune capacity to effectively target and destroy cancer cells, inducing a form of cell death called autosis.
Extracellular vesicles and exosomes are membrane-bound vesicles that facilitate intercellular exchange of proteins, lipids, and genetic material. They will be highlighted in upcoming events focusing on mitochondrial quality control, skin ageing, and microbiota.
Researchers at Gladstone Institutes and UCSF have developed a new approach to introduce long DNA sequences into cells with remarkable efficiency. The technology, which uses single-stranded DNA templates, overcomes the limitations of traditional viral vectors and has the potential to make cell therapies faster, better, and less expensive.
A University of Houston engineer has developed technology to determine which patients are likely to respond to CAR T-cell therapy for lymphoma, saving time and increasing success rates. The TIMING method analyzes interactions between T cells and tumor cells, identifying a key ligand molecule that predicts patient response.
Scientists have elucidated the regulatory functions of Pan1p, a key player in late-stage clathrin-mediated endocytosis. The protein drives actin assembly and disassembly, facilitating vesicle internalization.
Researchers at Terasaki Institute create micro-organospheres for direct viral infection, immune cell penetration, and high-throughput therapeutic drug screening. The technology holds promise for personalized medicine, tumor therapy and rapid drug testing.
Researchers at McMaster University have discovered a combination of antiviral drugs and antibody therapies that is more effective than either approach alone. The combination boosts the virus-fighting properties of antibodies, which work by binding to infected cells and triggering the immune system to kill them.
The study found an overall response rate of 57% and disease control rate of 83% in 23 patients with diverse cancer types. These results validate RET as a tissue-agnostic target with sensitivity to RET inhibition.
A study published in eLife identified three microRNAs that may impair healing in venous ulcers, a common type of chronic wound. The findings suggest that drugs targeting these microRNAs could help facilitate healing in patients, offering new approaches for treating this painful and slow-to-heal condition.
A research team at the University of Oklahoma has developed a new approach to triggering an adaptive immune response. The study presents a method to create molecules that can integrate into cells, cause stress on their membrane, and release signals that recruit immune cells to their location.
A novel subset of CD8+ regulatory-like T cells (CD8+TRLs) has been identified as 'first responders' to stroke, providing fast-acting and lasting protection. These cells reach the brain within 24 hours after stroke onset, releasing molecules that provide direct neuroprotective effects.
Researchers used a new 3D imaging technique to analyze the interaction between T-cell therapies and solid mini-tumors, revealing a wide variety of behaviors in engineered T cells. The study identified specific gene signatures of highly potent T cells that can target multiple tumor cells.
Researchers discovered cancer cells produce a unique collagen that alters the tumor microbiome and promotes cancer progression. Loss of this collagen reduces cancer cell proliferation and boosts anti-tumor immune response, offering a potential therapeutic strategy.
Researchers have developed a new quantitative approach to predict and customize site-specific recombination, enabling more efficient genetic and cell therapies. The tool combines high-throughput experiments with machine learning models to control the rate of DNA editing, paving the way for personalized treatment.
Researchers from Rice University, Duke University, Brown University and Baylor College of Medicine developed a magnetic technology to wirelessly control neural circuits in fruit flies. They used genetic engineering to express heat-sensitive ion channels in neurons that control the behavior, and iron nanoparticles to activate the channels.
A new AI technology called in silico FOCUS analyzes cell images to predict therapeutic effect of drugs for neurodegenerative disorders like Kennedy disease. The technology has 100% accuracy and can analyze several hundred thousand cells in just a few minutes.
Researchers found specific T-cell populations expanded after immune therapy treatment, predicting which patients would respond best to the treatment. These biomarkers could help select patients for future trials to improve outcomes.
Researchers have found that high levels of iron can generate toxic free radicals, which damage lipids and ultimately lead to cell death. The team is exploring the use of compounds like JKE-1674 to induce ferroptosis in prostate cancer cells, making them more vulnerable to treatment.
Researchers at A*STAR's Institute of Molecular and Cell Biology developed a bio-functional thermogel that prevents retinal scarring in pre-clinical models. The thermogel modulates cellular behavior to prevent scar membrane formation, offering a novel therapy for proliferative vitreoretinopathy.
Researchers have discovered a unique biochemical profile in severe asthmatic patients, which could lead to more effective treatments. The study found a decrease in carnitine metabolism in severe asthmatics, playing an important role in cellular energy generation and immune responses.
Researchers have discovered a protein produced by soft-tissue sarcoma tumors that changes the biology of surrounding immune cells, promoting tumor growth. The study could lead to improved treatments for this rare and aggressive cancer type.
A new study reveals that IL18 signaling is essential for β-cell development and insulin secretion, using specific receptors on acinar and β cells. This finding may provide insights into the role of IL18 in regulating islet β cell proliferation and guide future efforts to expand β cells and increase islet mass in diabetes.
Researchers have discovered the process of incorporating selenium into 25 specialized proteins, essential for various cellular and metabolic processes. The study provides critical insights into the workings of these vital mechanisms, which could lead to the development of new medical therapies.
A world-class team led by Dr. Catherine Bollard aims to develop novel immunotherapy treatments for children with solid cancers, aiming to improve survival and diminish lifelong toxicities. The team will receive $25m funding to tackle the challenging issue of solid tumors in children.
Researchers have discovered a new treatment that combines CAR-T cell therapy with interleukin-7 to enhance its effectiveness in treating blood cancers. The treatment results in significantly increased anti-tumor activity, improved survival rates, and reduced tumor growth in mice.
Researchers have reported encouraging early-stage data for the Phase 1 clinical trial of INB-200, a gamma-delta T cell-based immunotherapy. All patients enrolled in the trial have exceeded their expected progression-free survival, with two patients exceeding overall survival as well. The treatment shows promising activity against gliob...
Researchers at CMU propose a new cell delivery method using shrink-wrapped corneal endothelial cells as an alternative to cornea transplant. The technology enables rapid engraftment into intact tissues, showing promise in treating diseases such as cystic fibrosis and heart attack.
Researchers found that severe asthma patients produce growth factors that block corticosteroids from working, leading to frequent breathing problems. This discovery may lead to new treatments targeting these growth factors to improve outcomes for patients with severe asthma.
MD Anderson research highlights new treatments for skin cancers, including novel therapies. The institution also showcased improved goals of care programs, which demonstrated significant reductions in ICU mortality and improved patient outcomes during the COVID-19 pandemic.
Researchers from CAMP have identified a secreted metabolite biomarker, nicotinic acid to nicotinamide ratio, to detect microbial contaminations in human cell therapy products. This method enables early-stage detection of microbial contaminants and differentiates between live and dead bacteria.
The Edmonton Protocol team has reported that islet transplantation is an effective therapy for patients with difficult-to-control Type 1 diabetes, with a high rate of graft survival and insulin independence. The procedure has been shown to stabilize blood sugar levels and improve quality of life for patients.
Researchers developed a droplet-based microfluidic technology to produce micro-organospheres from cancer patient biopsies within an hour. These miniature tumors retain the original microenvironment and can be used for testing many drug conditions, showing almost perfect correlation with actual clinical treatment outcomes.
Researchers successfully reprogrammed non-controllers' CD8+ T cells to acquire properties of natural HIV controllers, enabling them to suppress viral load and survive without exhaustion. This breakthrough could lead to a cell therapy strategy for achieving HIV remission, with potential applications in cancer treatments.
Researchers identified OR2H1 as an effective target for CAR T cells in solid tumors, inhibiting growth in lung and ovarian cancer. The study suggests that targeting this protein could lead to the development of new CAR T therapies for a wide variety of patients with solid tumors.
José McFaline-Figueroa, a genomicist at Columbia University, has received a three-year NSF CAREER Award to investigate how cancer cells respond to anti-cancer therapy. His research aims to understand the molecular changes induced in aggressive cancer cells after exposure to treatment and how these changes alter response to treatment.
Researchers at Massachusetts General Hospital have developed a novel CAR T-cell construct that targets acute myeloid leukemia (AML) effectively. The combination of drug therapy and engineering approaches enhanced the treatment's ability to adhere to tumor cells, overcoming previous difficulties with antigen targeting.
Researchers at St. Jude Children's Research Hospital found that EGFR inhibitor treatment can target and kill persistent cancer cells in rhabdomyosarcoma, a type of soft tissue cancer common in children. The study's results support a new clinical trial strategy for treating the disease.
The ESMO Breast Cancer Congress 2022 event will present more than 200 studies on various aspects of breast cancer, including new treatments and innovative clinical practices. The congress will be held onsite in Berlin, Germany, and online, offering a platform for breast cancer specialists to share knowledge and improve patient outcomes.
Researchers have shed light on how immune checkpoint protein LAG3 modulates T cell activity, providing crucial information for the development of new LAG3-blocking therapies. The study found that LAG3 suppresses T cell activation by disrupting coreceptor-Lck association, even in the absence of MHC Class II molecules.
Researchers load CAR-T cells with an oncolytic virus to target and kill solid cancer tumors, providing a potent immune response. The combination approach overcomes challenges in treating solid tumors with CAR-T cell therapy alone.
Researchers have discovered that vesicles from human heart cells can repair damaged tissue and prevent lethal heart rhythm disorders. The treatment, using cardiosphere-derived cells (CDCs) and their secreted exosomes, showed improved heart rhythms and reduced scarring in animal models.